Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

John T. Mullen, M.D.

Co-Author

This page shows the publications co-authored by John Mullen and Jeffrey Clark.
Connection Strength

1.164
  1. Impact of Treatment Sequencing on Survival for Patients with Locally Advanced Gastric Cancer. Ann Surg Oncol. 2021 May; 28(5):2856-2865.
    View in: PubMed
    Score: 0.228
  2. Impact of Postoperative Complication and Completion of Multimodality Therapy on Survival in Patients Undergoing Gastrectomy for Advanced Gastric Cancer. J Am Coll Surg. 2020 06; 230(6):912-924.
    View in: PubMed
    Score: 0.214
  3. The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality. J Surg Oncol. 2016 Apr; 113(5):560-4.
    View in: PubMed
    Score: 0.162
  4. Adjuvant Therapy Completion Rates in Patients with Gastric Cancer Undergoing Perioperative Chemotherapy Versus a Surgery-First Approach. J Gastrointest Surg. 2016 Jan; 20(1):172-9; discussion 179.
    View in: PubMed
    Score: 0.158
  5. ASO Visual Abstract: Neoadjuvant versus Postoperative Chemoradiotherapy Is Associated with Improved Survival in Patients with Resectable Gastric and Gastroesophageal Cancer. Ann Surg Oncol. 2021 Dec; 28(Suppl 3):690-691.
    View in: PubMed
    Score: 0.060
  6. Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer. Ann Surg Oncol. 2022 Jan; 29(1):242-252.
    View in: PubMed
    Score: 0.060
  7. Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. Clin Cancer Res. 2021 12 01; 27(23):6343-6353.
    View in: PubMed
    Score: 0.059
  8. Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers. Oncologist. 2020 11; 25(11):e1691-e1700.
    View in: PubMed
    Score: 0.056
  9. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. J Natl Cancer Inst. 2017 09 01; 109(9).
    View in: PubMed
    Score: 0.045
  10. A protein and mRNA expression-based classification of gastric cancer. Mod Pathol. 2016 07; 29(7):772-84.
    View in: PubMed
    Score: 0.041
  11. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016 Feb 10; 34(5):460-8.
    View in: PubMed
    Score: 0.040
  12. Familial Gastric Cancers. Oncologist. 2015 Dec; 20(12):1365-77.
    View in: PubMed
    Score: 0.040
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.